Drug Profile
Research programme: chimeric immunomodulatory DNA - Dynavax
Alternative Names: Chimeric immunomodulatory compounds - Dynavax; Chimeric immunomodulatory oligonucleotides - Dynavax; CIC - DynavaxLatest Information Update: 16 Apr 2008
Price :
$50
*
At a glance
- Originator Dynavax Technologies
- Class Oligonucleotides
- Mechanism of Action Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation; Viral infections
Most Recent Events
- 16 Apr 2008 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 16 Apr 2008 Discontinued - Preclinical for Viral infections in USA (unspecified route)
- 25 Sep 2006 Chimeric immunomodulatory DNA compounds are still in preclinical trials in the US